RA
| |
Rosalind Advisors, Inc.13F | |
| Rosalind Advisors, Inc. | |
| Last update 2025-05-14 | 34 Stocks (7 new) |
| Value $206.00 Mil | Turnover 27 % |
Rosalind Advisors, Inc. Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DCTH | Delcath Systems Inc | 2,900,389 | 29,003.9 | +9.43% | 14.100 | +1.22% | 8.680 | +19.23% | +2.49% | 429.8 | Medical Devices & Instruments | |
VSTM | Verastem Inc | 2,644,517 | 15,946.4 | +193.84% | 7.750 | +5.11% | 5.140 | +1.40% | -8.90% | 258.8 | Biotechnology | |
XERS | Xeris Biopharma Holdings Inc | 2,495,986 | 13,703.0 | -19.61% | 6.660 | -1.06% | 1.560 | +15.50% | +40.71% | 763.9 | Biotechnology | |
MYO | Myomo Inc | 2,703,661 | 13,004.6 | -9.85% | 6.320 | -0.97% | 7.510 | -52.93% | -67.55% | 75.2 | Medical Devices & Instruments | |
IDYA | IDEAYA Biosciences Inc | 700,000 | 11,466.0 | New Holding | 5.580 | +5.58% | 0.800 | +47.93% | -16.54% | 1,878.6 | Biotechnology | |
FENC | Fennec Pharmaceuticals Inc | 1,782,844 | 10,857.5 | +41.51% | 5.280 | +1.55% | 6.460 | +73.65% | +37.66% | 242.3 | Biotechnology | |
URGN | UroGen Pharma Ltd | 950,000 | 10,507.0 | +9.20% | 5.110 | +0.43% | 2.060 | +41.93% | +28.73% | 632.1 | Biotechnology | |
OCUL | Ocular Therapeutix Inc | 1,218,700 | 8,933.1 | +7.97% | 4.340 | +0.32% | 0.770 | +64.78% | +16.16% | 1,580.3 | Biotechnology | |
ABEO | Abeona Therapeutics Inc | 1,805,817 | 8,595.7 | +0.02% | 4.180 | 0% | 3.700 | +35.19% | +4.85% | 298.8 | Biotechnology | |
REPL | Replimune Group Inc | 850,000 | 8,287.5 | +226.92% | 4.030 | +2.80% | 1.100 | +30.81% | -22.87% | 720.0 | Biotechnology |
Rosalind Advisors, Inc.'s Historical Top Holdings Breakdowns
Rosalind Advisors, Inc.'s Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
IDYA | IDEAYA Biosciences Inc | 2025-03-31 | New Buy New Buy | +5.58% | 16.38 ($21.31) 26 | $21.45 | 0.66% | New holding | 700,000 | 700,000 | |
| CMRX Unlock Delisted | Chimerix Inc | 2025-03-31 | Sold Out Sold Out | -5.44% | 3.25 ($5.52) 8.52 | $8.54 | 54.71% | Sold Out | 0 | -3,050,000 | |
VSTM | Verastem Inc | 2025-03-31 | Add Add | +5.11% | 5.04 ($6.11) 7.53 | $4.71 | -22.91% | Add 193.84% | 2,644,517 | 1,744,517 | |
VRDN | Viridian Therapeutics Inc | 2025-03-31 | New Buy New Buy | +3.90% | 13.48 ($17.03) 20.91 | $16.05 | -5.75% | New holding | 595,000 | 595,000 | |
REPL | Replimune Group Inc | 2025-03-31 | Add Add | +2.80% | 9.75 ($12.38) 14.31 | $9.34 | -24.56% | Add 226.92% | 850,000 | 590,000 | |
OPTN | OptiNose Inc | 2025-03-31 | Reduce Reduce | -2.12% | 5 ($6.28) 9.17 | $9.60 | 52.87% | Reduce -70.79% | 256,190 | -620,806 | |
NUVB | Nuvation Bio Inc | 2025-03-31 | New Buy New Buy | +2.10% | 1.76 ($2.28) 3.25 | $2.05 | -10.09% | New holding | 2,451,500 | 2,451,500 | |
PHVS | Pharvaris NV | 2025-03-31 | New Buy New Buy | +1.71% | 14.9 ($16.87) 19.54 | $17.98 | 6.58% | New holding | 223,627 | 223,627 | |
FENC | Fennec Pharmaceuticals Inc | 2025-03-31 | Add Add | +1.55% | 5.54 ($6.42) 7.02 | $8.70 | 35.51% | Add 41.51% | 1,782,844 | 522,968 | |
DCTH | Delcath Systems Inc | 2025-03-31 | Add Add | +1.22% | 11.48 ($14.19) 16.45 | $12.34 | -13.04% | Add 9.43% | 2,900,389 | 250,000 |
Rosalind Advisors, Inc. Total Holding History ($B)
Rosalind Advisors, Inc.'s Asset Allocation
Rosalind Advisors, Inc. Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Rosalind Advisors, Inc.'s Hypothetical Growth since 2025-03-31
Rosalind Advisors, Inc.'s Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Rosalind Advisors, Inc.'s Holdings Heat Map
Size field:
Rosalind Advisors, Inc.'s Holdings Bubble Chart
Rosalind Advisors, Inc. News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers